KR101831638B1 - 비-알코올성 지방간 질환의 예방 및 치료를 위한 아데노바이러스 ad36 e4orf1 단백질 - Google Patents

비-알코올성 지방간 질환의 예방 및 치료를 위한 아데노바이러스 ad36 e4orf1 단백질 Download PDF

Info

Publication number
KR101831638B1
KR101831638B1 KR1020137001869A KR20137001869A KR101831638B1 KR 101831638 B1 KR101831638 B1 KR 101831638B1 KR 1020137001869 A KR1020137001869 A KR 1020137001869A KR 20137001869 A KR20137001869 A KR 20137001869A KR 101831638 B1 KR101831638 B1 KR 101831638B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
liver
adenovirus
treatment
e4orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137001869A
Other languages
English (en)
Korean (ko)
Other versions
KR20130100262A (ko
Inventor
닉힐 두란드하르
Original Assignee
보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지 filed Critical 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지
Publication of KR20130100262A publication Critical patent/KR20130100262A/ko
Application granted granted Critical
Publication of KR101831638B1 publication Critical patent/KR101831638B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137001869A 2010-07-08 2011-07-08 비-알코올성 지방간 질환의 예방 및 치료를 위한 아데노바이러스 ad36 e4orf1 단백질 Expired - Fee Related KR101831638B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36244310P 2010-07-08 2010-07-08
US61/362,443 2010-07-08
PCT/US2011/043338 WO2012006512A1 (en) 2010-07-08 2011-07-08 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
KR20130100262A KR20130100262A (ko) 2013-09-10
KR101831638B1 true KR101831638B1 (ko) 2018-02-23

Family

ID=44629893

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137001869A Expired - Fee Related KR101831638B1 (ko) 2010-07-08 2011-07-08 비-알코올성 지방간 질환의 예방 및 치료를 위한 아데노바이러스 ad36 e4orf1 단백질

Country Status (11)

Country Link
US (2) US8951980B2 (https=)
EP (1) EP2590665B1 (https=)
JP (1) JP5965397B2 (https=)
KR (1) KR101831638B1 (https=)
CN (1) CN103052397B (https=)
AU (1) AU2011274537B9 (https=)
CA (1) CA2803787C (https=)
ES (1) ES2550962T3 (https=)
NZ (1) NZ606236A (https=)
TW (1) TWI531650B (https=)
WO (1) WO2012006512A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618374T3 (es) 2012-10-17 2017-06-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Composiciones y métodos para mejorar la absorción de glucosa
US9354963B2 (en) * 2014-02-26 2016-05-31 Microsoft Technology Licensing, Llc Service metric analysis from structured logging schema of usage data
US10047107B2 (en) 2014-04-23 2018-08-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Small molecule analogs of E4orf1
GB201910299D0 (en) * 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064836A1 (en) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
US20060045919A1 (en) 2004-08-27 2006-03-02 Samueli Institute Homeopathic compositions and methods for the treatment of cancer
JP2008105945A (ja) * 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064836A1 (en) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses

Also Published As

Publication number Publication date
NZ606236A (en) 2014-09-26
TW201217529A (en) 2012-05-01
US20120027845A1 (en) 2012-02-02
TWI531650B (zh) 2016-05-01
EP2590665B1 (en) 2015-09-16
EP2590665A1 (en) 2013-05-15
HK1185261A1 (en) 2014-02-14
KR20130100262A (ko) 2013-09-10
JP2013531681A (ja) 2013-08-08
AU2011274537B9 (en) 2017-02-23
ES2550962T3 (es) 2015-11-13
JP5965397B2 (ja) 2016-08-03
WO2012006512A1 (en) 2012-01-12
CA2803787A1 (en) 2012-01-12
AU2011274537B2 (en) 2016-12-15
CN103052397B (zh) 2017-09-19
US8951980B2 (en) 2015-02-10
CN103052397A (zh) 2013-04-17
CA2803787C (en) 2018-12-04
US20170340699A1 (en) 2017-11-30
AU2011274537A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
JP5767314B2 (ja) Ｆｇｆを用いて代謝障害を処置するための方法
Trevaskis et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
Slosberg et al. Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein
Bai et al. F‐box/WD repeat‐containing protein 5 mediates the ubiquitination of apoptosis signal‐regulating kinase 1 and exacerbates nonalcoholic steatohepatitis in mice
Krishnapuram et al. Template to improve glycemic control without reducing adiposity or dietary fat
KR101831638B1 (ko) 비-알코올성 지방간 질환의 예방 및 치료를 위한 아데노바이러스 ad36 e4orf1 단백질
US9468690B2 (en) Decorin gene delivery system and cancer treatment
KR102738851B1 (ko) 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도
JP6135945B2 (ja) 褐色脂肪細胞分化誘導剤
Li et al. Pancreatic acinar-specific overexpression of Reg2 gene offered no protection against either experimental diabetes or pancreatitis in mice
US20200377565A1 (en) Brown Fat-Selective Adipokines
HK1185261B (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2023010049A1 (en) Therapeutic uses of isthmin protein
JP2019529479A (ja) 患者におけるｉｓｈａｋ線維症ステージに基づいた肝線維症の軽減方法及びライソゾーム酸性リパーゼ欠損症の治療方法
US20250281572A1 (en) Compositions and methods for treating and preventing metabolic disorders
WO2020223674A2 (en) Methods and compositions for regulating adipogenesis
US20090326048A1 (en) Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes
CN103585629B (zh) 一种防治胰岛素抵抗及其相关疾病的靶标
KR20250052370A (ko) 중증 고중성지방혈증용 조성물 및 치료 방법
Cefalu et al. Template to improve glycemic control without
WO2010037224A1 (en) Method for preventing and treating cardiovascular diseases with brca1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210220

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210220